Charles River Laboratories International, Inc. Expected to Post Q4 2024 Earnings of $2.82 Per Share (NYSE:CRL)

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities research analysts at Zacks Research increased their Q4 2024 EPS estimates for Charles River Laboratories International in a research report issued on Monday, September 4th. Zacks Research analyst M. Mondal now expects that the medical research company will earn $2.82 per share for the quarter, up from their prior estimate of $2.79. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.48 per share.

CRL has been the topic of several other research reports. JPMorgan Chase & Co. increased their target price on Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, September 2nd. Wells Fargo & Company decreased their price target on shares of Charles River Laboratories International from $290.00 to $280.00 in a report on Friday, May 12th. Citigroup downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $260.00 to $225.00 in a research note on Monday, July 10th. Finally, Credit Suisse Group lowered their price target on Charles River Laboratories International from $260.00 to $255.00 in a report on Friday, May 12th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $247.80.

Charles River Laboratories International Stock Down 0.0 %

Shares of NYSE:CRL opened at $204.42 on Thursday. The company has a 50 day moving average of $206.84 and a 200-day moving average of $204.05. The stock has a market cap of $10.48 billion, a price-to-earnings ratio of 21.68, a P/E/G ratio of 1.83 and a beta of 1.33. Charles River Laboratories International has a one year low of $181.22 and a one year high of $262.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.49 and a quick ratio of 1.21.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 9th. The medical research company reported $2.69 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.06. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. Charles River Laboratories International’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.77 EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Venturi Wealth Management LLC acquired a new stake in Charles River Laboratories International during the first quarter worth approximately $25,000. Lindbrook Capital LLC increased its position in shares of Charles River Laboratories International by 97.0% in the second quarter. Lindbrook Capital LLC now owns 132 shares of the medical research company’s stock worth $28,000 after purchasing an additional 65 shares during the period. Desjardins Global Asset Management Inc. acquired a new position in Charles River Laboratories International in the first quarter valued at about $30,000. Tsfg LLC lifted its position in Charles River Laboratories International by 49.1% during the second quarter. Tsfg LLC now owns 158 shares of the medical research company’s stock worth $33,000 after purchasing an additional 52 shares during the period. Finally, HighMark Wealth Management LLC acquired a new stake in Charles River Laboratories International during the first quarter worth about $45,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In other news, VP William D. Barbo sold 5,763 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $217.24, for a total value of $1,251,954.12. Following the transaction, the vice president now directly owns 3,592 shares of the company’s stock, valued at $780,326.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP William D. Barbo sold 5,763 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $217.24, for a total transaction of $1,251,954.12. Following the transaction, the vice president now owns 3,592 shares in the company, valued at $780,326.08. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Michael Gunnar Knell sold 1,471 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $216.54, for a total value of $318,530.34. Following the transaction, the chief accounting officer now owns 9,940 shares in the company, valued at approximately $2,152,407.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,934 shares of company stock valued at $1,722,048. 1.30% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).